<DOC>
	<DOCNO>NCT01536652</DOCNO>
	<brief_summary>This study conduct Europe . The aim observational study document glycaemic parameter , adverse event , include drug reaction , well hypoglycaemic episode , patient switch insulin glargine combine oral antidiabetic drug ( OADs ) biphasic insulin aspart 30 ( NovoMixÂ® 30 ) combine OADs , applicable .</brief_summary>
	<brief_title>Prandial Orientated Biphasic Insulin Aspart 30 Therapy - Physiological Premix Insulin Therapy Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects diabetes mellitus type 2</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>